Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AKRO | Common Stock | Award | $9.25K | +1.15K | +35.15% | $8.03* | 4.43K | Jun 30, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AKRO | Stock Option (Right to Buy) | Award | $0 | +29.1K | $0.00 | 29.1K | Sep 9, 2022 | Common Stock | 29.1K | $21.10 | Direct | F2 | |
transaction | AKRO | Stock Option (Right to Buy) | Award | $0 | +29.1K | +100% | $0.00 | 58.1K | Sep 13, 2022 | Common Stock | 29.1K | $21.10 | Direct | F3 |
Id | Content |
---|---|
F1 | These shares were acquired on June 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
F2 | On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option. |
F3 | On December 8, 2021, the Reporting Person was granted an option to purchase 87,221 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 29,074 shares underlying such option. |